Olema Oncology, Inc. OLMA
7.25 USD +0.03 (+0.35%)
As ofNov 18, 2026, 2:30 PM EST
7.07 Day range 7.50
6.24 52-week range 36.26
- YTD
- -71.02%
- 1 year
- -64.03%
News
benzinga.com Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancerKAT6A degradation was active in both ESR1-mutant and wild-type…
seekingalpha.com Olema Oncology, Inc. (OLMA) Olema Pharmaceuticals, Inc. Presents at UBS Global Biopharma Conference 2026 Transcript Olema Oncology, Inc. ( OLMA ) Olema Pharmaceuticals, Inc. UBS Global Biopharma Conference 2026 November 17, 2026 10:20 AM EST Company Participants Sean Bohen - President, CEO & Director Conference…
globenewswire.com Olema Oncology to Participate in Upcoming Investor Conferences SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…
seekingalpha.com Olema Pharmaceuticals, Inc. (OLMA) Presents at Stifel 2026 Healthcare Conference 2026 Transcript Olema Pharmaceuticals, Inc. ( OLMA ) Stifel 2026 Healthcare Conference 2026 November 11, 2026 10:40 AM EST Company Participants Sean Bohen - President, CEO & Director Conference Call Participants…
globenewswire.com Olema Oncology Announces Corporate Name Change SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company…benzinga.com Olema Pharmaceuticals Q3 EPS $(0.73) Misses $(0.63) Estimate Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.63) by 17.74 percent. This is a 48.98 percent decrease over…
